Med-life discoveries
Med-life Discoveries is a clinical-stage biopharma company dedicated to developing novel plasmalogen-based therapeutics for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP) and other neurological conditions. The company is focused on advancing therapies through regulatory safety and efficacy studies, aiming to address unmet medical needs in neurological disorders.
Industries
Nr. of Employees
small (1-50)
Med-life discoveries
Patents
Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject
US-10697969-B2
View DetailsSerum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US-10656155-B2
View DetailsMethods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
US-10302624-B2
View DetailsSerum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US-10024857-B2
View Details
Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject
US-10697969-B2
View DetailsSerum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US-10656155-B2
View DetailsMethods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
US-10302624-B2
View DetailsSerum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US-10024857-B2
View DetailsProducts
Clinical-stage plasmalogen augmentation therapeutic (investigational)
Investigational plasmalogen augmentation therapeutic in clinical development for plasmalogen-deficient peroxisomal disorders and other neurological conditions; undergoing formal regulatory safety and efficacy studies and not commercially available.
Clinical-stage plasmalogen augmentation therapeutic (investigational)
Investigational plasmalogen augmentation therapeutic in clinical development for plasmalogen-deficient peroxisomal disorders and other neurological conditions; undergoing formal regulatory safety and efficacy studies and not commercially available.
Services
Orderable kit for measurement of plasmalogen-related biomarkers.
Collaborative testing and preclinical studies with academic and clinical partners to evaluate therapeutic candidates.
Orderable kit for measurement of plasmalogen-related biomarkers.
Collaborative testing and preclinical studies with academic and clinical partners to evaluate therapeutic candidates.
Expertise Areas
- Clinical trial management (Phase I)
- Lipidomics and bioanalysis
- Preclinical disease model development
- Neurodegenerative disease therapeutics
Key Technologies
- Plasmalogen (ether-lipid) augmentation therapeutics
- LC-MS/MS lipidomics
- Animal disease models (mouse)
- Pharmacokinetic analysis
News & Updates
Jun 24, 2025 - Catch up on our latest whereabouts and milestones here!
MLD’s plasmalogen therapeutics are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.
Mar 31, 2025 - MLD announces publication of RhizoQOL survey.
Mar 17, 2025 - First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD.
Jan 16, 2025 - MLD announces plans for Rare Disease Day 2025.
Jun 24, 2025 - Catch up on our latest whereabouts and milestones here!
MLD’s plasmalogen therapeutics are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.
Mar 31, 2025 - MLD announces publication of RhizoQOL survey.
Mar 17, 2025 - First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD.
Jan 16, 2025 - MLD announces plans for Rare Disease Day 2025.